Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer
TLDR
EBRT+HDR-BTb resulted in a significant improvement in RFS compared to EBRT alone with a 31% reduction in the risk of recurrence and similar incidence of severe late urinary and rectal morbidity.About:
This article is published in Radiotherapy and Oncology.The article was published on 2012-05-01 and is currently open access. It has received 421 citations till now. The article focuses on the topics: Brachytherapy & External beam radiotherapy.read more
Citations
More filters
Journal ArticleDOI
The Diagnosis and Treatment of Prostate Cancer: A Review.
Mark S. Litwin,Hung-Jui Tan +1 more
TL;DR: Advances in the diagnosis and treatment of prostate cancer have improved the ability to stratify patients by risk and allowed clinicians to recommend therapy based on cancer prognosis and patient preference.
Journal ArticleDOI
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
W. James Morris,W. James Morris,Scott Tyldesley,Sree Rodda,Ross Halperin,Howard Pai,Michael McKenzie,Michael McKenzie,G. Duncan,Gerard Morton,Jeremy Hamm,Nevin Murray +11 more
TL;DR: Compared with 78 Gy EBRT, men randomized to the LDR-PB boost were twice as likely to be free of biochemical failure at a median follow-up of 6.5 years and no significant overall survival difference was observed between the treatment arms.
Journal ArticleDOI
Past, present, and future of radiotherapy for the benefit of patients.
TL;DR: The timeline of 100 years of radiotherapy is reviewed with a focus on breakthroughs in the physics of radi therapy and technology during the past two decades, and the associated clinical benefits.
Journal ArticleDOI
Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines
James L. Mohler,Andrew J. Armstrong,Robert R. Bahnson,Barry Boston,J. Erik Busby,Anthony V. D'Amico,James A. Eastham,Charles Arthur Enke,Thomas A. Farrington,Celestia S. Higano,Eric M. Horwitz,Philip W. Kantoff,Mark H. Kawachi,Michael Kuettel,Richard T. Lee,Gary R. MacVicar,Arnold W. Malcolm,David Miller,Elizabeth R. Plimack,Julio M. Pow-Sang,Mack Roach,Eric M. Rohren,Stan Rosenfeld,Sandy Srinivas,Seth A. Strope,Jonathan D. Tward,Przemyslaw Twardowski,Patrick C. Walsh,Maria Ho,Dorothy A. Shead +29 more
TL;DR: Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurrent prostate cancer who have previously received docetaxel (category 1 recommendation).
Journal ArticleDOI
Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Amar U. Kishan,Ryan Cook,Jay P. Ciezki,Ashley E. Ross,Mark Pomerantz,Paul L. Nguyen,Talha Shaikh,Phuoc T. Tran,Kiri A. Sandler,Richard G. Stock,Gregory S. Merrick,D. Jeffrey Demanes,Daniel E. Spratt,Eyad Abu-Isa,Trude B. Wedde,Wolfgang Lilleby,Daniel J. Krauss,Grace Shaw,Ridwan Alam,Chandana A. Reddy,Andrew J. Stephenson,Eric A. Klein,Danny Y. Song,Jeffrey J. Tosoian,John V. Hegde,Sun Mi Yoo,Ryan Fiano,Anthony V. D'Amico,Nicholas G. Nickols,Nicholas G. Nickols,William J. Aronson,Ahmad Sadeghi,Stephen Greco,Curtiland Deville,Todd McNutt,Theodore L. DeWeese,Robert E. Reiter,J. Said,Michael L. Steinberg,Eric M. Horwitz,Patrick A. Kupelian,Patrick A. Kupelian,Christopher R. King +42 more
TL;DR: Among patients with Gleason score 9-10 prostate cancer, treatment with EBRT+BT with androgen deprivation therapy was associated with significantly better prostate cancer–specific mortality and longer time to distant metastasis.
References
More filters
Journal ArticleDOI
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach,Gerald E. Hanks,Howard D. Thames,Paul F. Schellhammer,William U. Shipley,Gerald H. Sokol,Howard M. Sandler +6 more
TL;DR: The panel recommended that investigators be allowed to use the ASTRO Consensus Definition after EBRT alone (no hormonal therapy) with strict adherence to guidelines as to "adequate follow-up."
Journal ArticleDOI
Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate : A randomized controlled trial
Anthony L. Zietman,Michelle DeSilvio,Jerry D. Slater,Carl J. Rossi,Daniel W. Miller,Judith Adams,William U. Shipley +6 more
TL;DR: Men with clinically localized prostate cancer have a lower risk of biochemical failure if they receive high-dose rather than conventional-dose conformal radiation, and this advantage was achieved without any associated increase in RTOG grade 3 acute or late urinary or rectal morbidity.
Journal ArticleDOI
Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer
Deborah A. Kuban,Susan L. Tucker,Lei Dong,George Starkschall,Eugene H. Huang,M. Rex Cheung,Andrew K. Lee,Alan Pollack +7 more
TL;DR: Modest escalation in radiotherapy dose improved freedom from biochemical and clinical progression with the largest benefit in prostate cancer patients with PSA >10 ng/ml.
Journal ArticleDOI
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial
David P. Dearnaley,Matthew R. Sydes,John Graham,Edwin Aird,David Bottomley,Richard A Cowan,Robert Huddart,Chakiath C Jose,John H L Matthews,Jeremy Millar,A. Rollo Moore,Rachel C Morgan,J. Martin Russell,Christopher D Scrase,Richard Stephens,Isabel Syndikus,Mahesh K. B. Parmar +16 more
TL;DR: The first analyses of effectiveness from the MRC RT01 randomised controlled trial are presented, finding Escalated-dose CFRT with neoadjuvant androgen suppression seems clinically worthwhile in terms of bPFS, progression-free survival, and decreased use of salvage androgens suppression.
Journal ArticleDOI
Is α/β for prostate tumors really low?
TL;DR: All the estimates point toward low values of α/β, at least as low as the estimates of Brenner and Hall, and possibly lower than the expected values of about 3 Gy for late complications.